Gabapentin Tablet
Product Images NDC 82804-249

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 82804-249). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

82804-249-90 (800 mg 100s)

Label for Gabapentin 800 mg tablets by Proficient Rx LP. The label indicates a quantity of 90 tablets, with 800 mg of gabapentin per tablet. It is film coated, oval shaped, and biconvex with debossed markings 'T' and '3'. Manufacturer information for Ascent Pharmaceuticals, Piscataway, NJ, is also shown, along with storage instructions at 25°C and a bar code.*

FDA Label Image

Clcr (Equation)

A formula for calculating creatinine clearance (CLCr) based on patient age, weight, serum creatinine levels, and a gender adjustment factor for females. The formula is displayed as an equation incorporating these variables.*

FDA Label Image

Figure-1 (Figure1)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1.' It compares mean pain scores over eight weeks between placebo (open circles) and Gabapentin 3600 mg/day (filled triangles). The x-axis is labeled 'Weeks' from Baseline to 8, and the y-axis is labeled 'Mean Pain Score' ranging from 0 to 10. Two 4-week periods are indicated: Dose Titration and Fixed Dose.*

FDA Label Image

Figure-2 (Figure2)

Line chart titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores over 7 weeks. The chart compares placebo and two gabapentin dose groups (1800 mg/day and 2400 mg/day) across a 3-week dose titration period followed by a 4-week fixed dose period. Pain scores decrease over time for gabapentin groups, with lower scores than placebo.*

FDA Label Image

Figure-3 (Figure3)

Bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing data from two studies. Study 1 compares placebo (12%) and GBP 3600 mg (29%) responders. Study 2 compares placebo (14%), GBP 1800 mg (32%), and GBP 2400 mg (34%) responders. Statistical significance is indicated with p-values <0.01 and <0.001.*

FDA Label Image

Figure-4 (Figure4)

A scatter plot chart titled 'Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study: Adjunctive Therapy Studies in Patients 12 Years of Age or Older with Partial Seizures.' The x-axis represents daily dose in mg (600, 900, 1200, 1800) and the y-axis shows difference percentage (%) ranging from 2 to 22. The chart includes data points for three studies labeled a, b, and c with respective responder rates at various gabapentin doses.*

FDA Label Image

Struc (Struct)

Chemical structure of gabapentin featuring a cyclohexane ring bonded to amino (CH2NH2) and carboxyl (CH2CO2H) functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.